Kaiser Permanente HIV Cohort Study
- Conditions
- AIDSHIV
- Interventions
- Other: non-interventional trial
- First Posted Date
- 2011-04-20
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 282368
- Registration Number
- NCT01339403
A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese Subjects
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 10
- Registration Number
- NCT01332565
- Locations
- πΊπΈ
GSK Investigational Site, Cypress, California, United States
EuroSIDA As An External Comparator To MOTIVATE Trials
- Conditions
- HIVAIDS
- Interventions
- Other: maraviroc
- First Posted Date
- 2011-04-06
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 1181
- Registration Number
- NCT01329783
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 183
- Registration Number
- NCT01328041
- Locations
- πͺπΈ
GSK Investigational Site, Sevilla, Spain
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 138
- Registration Number
- NCT01327547
- Locations
- πΊπΈ
AIDS Research Alliance, Los Angeles, California, United States
πΊπΈGeorgia Regents Medical Center, Augusta, Georgia, United States
πΊπΈSaint Michael's Medical Center, Newark, New Jersey, United States
Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2011-02-04
- Last Posted Date
- 2011-06-29
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 28
- Registration Number
- NCT01290211
- Locations
- π§πͺ
Pfizer Investigational Site, Bruxelles, Belgium
A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.
- Conditions
- Infection, Human Immunodeficiency Virus I
- Interventions
- First Posted Date
- 2011-01-25
- Last Posted Date
- 2014-12-24
- Lead Sponsor
- ViiV Healthcare
- Registration Number
- NCT01283100
- Locations
- πΊπΈ
GSK Investigational Site, Buffalo, New York, United States
Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia
- Conditions
- HIV
- Interventions
- Drug: HIV therapy
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2014-03-03
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 98
- Registration Number
- NCT01275625
- Locations
- π·πΊ
Moscow regional center on AIDS and infectious diseases prophylaxis and control, Moscow, Russian Federation
π·πΊFederal State Institution Republican clinical infectious hospital of Roszdrav, Saint-Petersburg, Russian Federation
π·πΊRegional Center on AIDS and Infectious Diseases Prophylaxis and Control, Nizhnij Novgorod, Russian Federation
A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Drug: 200mg [14C]- GSK2248761
- First Posted Date
- 2011-01-10
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- ViiV Healthcare
- Registration Number
- NCT01273103
- Locations
- πΊπΈ
GSK Investigational Site, Madison, Wisconsin, United States
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
- Conditions
- Infection, Human Immunodeficiency Virus I
- Interventions
- Drug: Abacavir/LamivudineDrug: Abacavir/Lamivudine Placebo
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 844
- Registration Number
- NCT01263015
- Locations
- π¬π§
GSK Investigational Site, Tooting, London, United Kingdom